Binimetinib is a selective MEK1 and MEK2 inhibitor, classified as a targeted signal transduction inhibitor, used primarily in combination therapy to treat unresectable or metastatic melanoma and metastatic… Read more
![Chemical structure of 1,3-Dioxoisoindolin-2-yl 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F13-Dioxoisoindolin-2-yl-5-4-bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxylate.png&w=3840&q=75)
![Chemical structure of 1-(4-Bromo-2-fluorophenyl)-8-fluoro-5-methyl-1,5-dihydro-3H-imidazo[4',5':4,5]benzo[1,2-c]isoxazol-3-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1-4-Bromo-2-fluorophenyl-8-fluoro-5-methyl-15-dihydro-3H-imidazo4545benzo12-cisoxazol-3-one.png&w=3840&q=75)


![Chemical structure of 2-((5-((4-Bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamido)oxy)ethyl acetate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-5-4-Bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxamidooxyethyl-acetate.png&w=3840&q=75)

![Chemical structure of 4-Fluoro-5-((2-fluorophenyl)amino)-1-methyl-1H-benzo[d]imidazole-6-carboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2649854-87-3-4-Fluoro-5-2-fluorophenylamino-1-methyl-1H-benzodimidazole-6-carboxylic-Acid.png&w=3840&q=75)
![Chemical structure of 4-Fluoro-5-((2-fluorophenyl)amino)-1-methyl-N-(2-(vinyloxy)ethoxy)-1H-benzo[d]imidazole-6-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2649854-88-4-4-Fluoro-5-2-fluorophenylamino-1-methyl-N-2-vinyloxyethoxy-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)
![Chemical structure of 5-((4-Bromo-2-fluorophenyl)(nitroso)amino)-4-fluoro-1-methyl-N-(2-(vinyloxy)ethoxy)-1H-benzo[d]imidazole-6-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-4-Bromo-2-fluorophenylnitrosoamino-4-fluoro-1-methyl-N-2-vinyloxyethoxy-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)
![Chemical structure of 5-((4-Bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-4-Bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxylic-Acid.png&w=3840&q=75)
![Chemical structure of 5-((4-Bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-N-(2-(vinyloxy)ethoxy)-1H-benzo[d]imidazole-6-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1415559-75-9-5-4-Bromo-2-fluorophenylamino-4-fluoro-1-methyl-N-2-vinyloxyethoxy-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)
![Chemical structure of 5-((4-Bromo-2-fluorophenyl)amino)-4-fluoro-N-hydroxy-1-methyl-1H-benzo[d]imidazole-6-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-4-Bromo-2-fluorophenylamino-4-fluoro-N-hydroxy-1-methyl-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)
![Chemical structure of 5-((4-Bromo-2-fluorophenyl)amino)-N'-(5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carbonyl)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carbohydrazide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-4-Bromo-2-fluorophenylamino-N-5-4-bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carbonyl-4-fluoro-1-methyl-1H-benzodimidazole-6-c.png&w=3840&q=75)
![Chemical structure of 5-((4-Bromo-2-fluorophenyl)amino)-N-(2-ethoxyethoxy)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-4-Bromo-2-fluorophenylamino-N-2-ethoxyethoxy-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)
![Chemical structure of 5-(4-Bromo-2-fluorophenyl)-4-fluoro-7-(2-hydroxyethoxy)-1,6-dimethyl-1,5,6,7-tetrahydro-8H-imidazo[4,5-g]quinazolin-8-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-4-Bromo-2-fluorophenyl-4-fluoro-7-2-hydroxyethoxy-16-dimethyl-1567-tetrahydro-8H-imidazo45-gquinazolin-8-one.png&w=3840&q=75)















![Chemical structure of Ethyl 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2509103-99-3-Ethyl-5-4-bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxylate.png&w=3840&q=75)

![Chemical structure of Methyl 4-fluoro-5-((2-fluorophenyl)amino)-1-methyl-1H-benzo[d]imidazole-6-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1415559-89-5-Methyl-4-fluoro-5-2-fluorophenylamino-1-methyl-1H-benzodimidazole-6-carboxylate.png&w=3840&q=75)
![Chemical structure of N,N'-(Ethane-1,2-diylbis(oxy))bis(5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FNN-Ethane-12-diylbisoxybis5-4-bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)
![Chemical structure of N-(2-(Aminooxy)ethoxy)-5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-2-Aminooxyethoxy-5-4-bromo-2-fluorophenylamino-4-fluoro-1-methyl-1H-benzodimidazole-6-carboxamide.png&w=3840&q=75)




Binimetinib is a selective MEK1 and MEK2 inhibitor, classified as a targeted signal transduction inhibitor, used primarily in combination therapy to treat unresectable or metastatic melanoma and metastatic non-small cell lung cancer characterized by specific BRAF mutations. This category contains a comprehensive range of high-quality reference standards essential for pharmaceutical analytical testing and quality control. Laboratories utilize these compounds, including structurally related impurities, degradation products, and metabolites like glucuronide conjugates, to perform accurate impurity profiling and facilitate method validation. Furthermore, the inclusion of stable isotope labelled compounds enables precise quantification and internal standard calibration during complex drug analysis. By providing access to these critical materials, including various N-nitroso and desmethyl derivatives, the catalogue supports the rigorous characterization and regulatory compliance required for the development and assessment of this antineoplastic therapeutic agent.